Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 9/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 4/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.40 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937101 | 0.91 | ATM (0.53) | CFDAURKARPS6KB1PDE5AADORA3 | |
| SCHEMBL4929205 | 0.91 | ATM (0.53) | CFDAURKARPS6KB1PDE5AADORA3 | |
| SCHEMBL20140289 | 0.89 | ADORA3 (0.45) | CFDAURKAPDPK1RPS6KB1PDE5A | |
| SCHEMBL6223849 | 0.88 | ADORA3 (0.42) | CFDAURKAPDPK1RPS6KB1PDE5A | |
| Hydrochloric Acid SCHEMBL6068508 | 0.87 | ADORA3 (0.42) | CFDAURKAPDPK1RPS6KB1PDE5A | |
| Acetic Acid SCHEMBL16245022 | 0.87 | ADORA3 (0.45) | CFDAURKAPDPK1RPS6KB1PDE5A | |
| SCHEMBL2878455 | 0.86 | PDE5A (0.40) | CFDAURKAPDPK1RPS6KB1PDE5A | |
| SCHEMBL8221670 | 0.86 | PDE5A (0.40) | CFDAURKAPDPK1RPS6KB1PDE5A | |
| SCHEMBL2878454 | 0.86 | PDE5A (0.40) | CFDAURKAPDPK1RPS6KB1PDE5A | |
| SCHEMBL15520222 | 0.85 | CFD (0.41) | CFDAURKAPDPK1RPS6KB1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135474-B2 | Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER HEALTHCARE AG (DE) | 2006-11-14 | — | — | US | disclosed |
| EP-1509228-B1 | DERIVATIVES OF 2-(1-BENZYL-1H-PYRAZOLO (3, 4-B)PYRIDINE-3YL) -5-(4-PYRIDINYL)-4-PYRIMIDINE AMINE AND THE USE THEREOF AS GUANYLATE CYCLASE STIMULATORS | BAYER HEALTHCARE AG (DE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-10-06 | — | — | US | disclosed |
| EP-1509228-A1 | DERIVATIVES OF 2-(1-BENZYL-1H-PYRAZOLO (3, 4-B)PYRIDINE-3YL) -5-(4-PYRIDINYL)-4-PYRIMIDINE AMINE AND THE USE THEREOF AS GUANYLATE CYCLASE STIMULATORS | Bayer HealthCare AG (DE) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097063-A1 | DERIVATIVES OF 2-(1-BENZYL-1H-PYRAZOLO (3, 4-B)PYRIDINE-3YL) -5-(4-PYRIDINYL)-4-PYRIMIDINE AMINE AND THE USE THEREOF AS GUANYLATE CYCLASE STIMULATORS | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | PDE3B, PDE5A, PDE3A | CFD 1484/4885AURKA 3894/4885PDPK1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.